Advertisement
Research Article Free access | 10.1172/JCI3094
Department of Haematology, Imperial College School of Medicine, Hammersmith Hospital, London W12 ONN, United Kingdom. mgordon@rpms.ac.uk
Find articles by Gordon, M. in: JCI | PubMed | Google Scholar
Department of Haematology, Imperial College School of Medicine, Hammersmith Hospital, London W12 ONN, United Kingdom. mgordon@rpms.ac.uk
Find articles by Marley, S. in: JCI | PubMed | Google Scholar
Department of Haematology, Imperial College School of Medicine, Hammersmith Hospital, London W12 ONN, United Kingdom. mgordon@rpms.ac.uk
Find articles by Lewis, J. in: JCI | PubMed | Google Scholar
Department of Haematology, Imperial College School of Medicine, Hammersmith Hospital, London W12 ONN, United Kingdom. mgordon@rpms.ac.uk
Find articles by Davidson, R. in: JCI | PubMed | Google Scholar
Department of Haematology, Imperial College School of Medicine, Hammersmith Hospital, London W12 ONN, United Kingdom. mgordon@rpms.ac.uk
Find articles by Nguyen, D. in: JCI | PubMed | Google Scholar
Department of Haematology, Imperial College School of Medicine, Hammersmith Hospital, London W12 ONN, United Kingdom. mgordon@rpms.ac.uk
Find articles by Grand, F. in: JCI | PubMed | Google Scholar
Department of Haematology, Imperial College School of Medicine, Hammersmith Hospital, London W12 ONN, United Kingdom. mgordon@rpms.ac.uk
Find articles by Amos, T. in: JCI | PubMed | Google Scholar
Department of Haematology, Imperial College School of Medicine, Hammersmith Hospital, London W12 ONN, United Kingdom. mgordon@rpms.ac.uk
Find articles by Goldman, J. in: JCI | PubMed | Google Scholar
Published August 15, 1998 - More info
The biological target for interferon (IFN)-alpha in chronic myeloid leukemia (CML) is unknown, but one possibility is that amplification of granulocyte-macrophage colony-forming cells (CFU-GM) is reduced. Replating CFU-GM colonies and observing secondary colony formation provides a measure of CFU-GM amplification. Amplification of CML, but not normal, CFU-GM in vitro was significantly inhibited by IFN-alpha (P = 0.02). In 5 out of 15 CML cases studied by fluorescence in situ hybridization, in vitro treatment with IFN-alpha increased the proportion of CFU-GM, which lacked BCR-ABL. The ability of patients' CFU-GM to amplify, and suppression of this ability by IFN-alpha, predicted responsiveness to IFN-alpha therapy in 86% of cases. Investigation of patients on treatment with IFN-alpha showed a threefold reduction in CFU-GM amplification in responders (P = 0.03) but no significant change in nonresponders (P = 0.8). We conclude that IFN-alpha preferentially suppresses amplification of CML CFU-GM to varying degrees. The differing in vitro sensitivities to IFN-alpha and growth kinetics of individual patients' cells could help differentiate those who will or will not benefit from treatment with IFN-alpha.